TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18546762

Group type: EXPERIMENTAL
Intervention: Direct composite resin core-crown reconstruction with a prefabricated metal post
Number of subjects: 87

Group type: COMPARATOR
Intervention: Direct composite resin core-crown reconstruction without a post (post-free)
Number of subjects: 87
Study: 16473223

Group type: EXPERIMENTAL
Intervention: LASIK treatment (bilateral, same-day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Post-LASIK treatment (surgical emmetropes)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Myopes not seeking refractive surgery (control group)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Natural emmetropes
Number of subjects: 59
Study: 12414404

Group type: EXPERIMENTAL
Intervention: Repeat LASIK
Number of subjects: 33

Group type: COMPARATOR
Intervention: Group 1 (>66 micro m) after primary LASIK
Number of subjects: 33
Study: 10502590

Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone (50 mg orally each morning for four months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (daily for four months)
Number of subjects: 24
Study: 8595540

Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 microgram twice daily
Number of subjects: 134

Group type: COMPARATOR
Intervention: Disodium cromoglycate, 20 mg four times daily
Number of subjects: 134
Study: 1955633

Group type: EXPERIMENTAL
Intervention: Cromolyn (20 mg via nebulizer, three times per day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (inhaled corticosteroid, dosage not specified, three times per day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (for both Cromolyn and Triamcinolone)
Number of subjects: 31
Study: 29306867

Group type: EXPERIMENTAL
Intervention: Screening by Lugol chromoendoscopy
Number of subjects: 33948

Group type: COMPARATOR
Intervention: No screening (Control)
Number of subjects: 33948
Study: 28611102

Group type: EXPERIMENTAL
Intervention: Intramuscular gentamicin and oral amoxicillin for 7 days at health posts
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 1011
Study: 25099730

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (32-34 °C)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Fever control (35.5-37 °C)
Number of subjects: 148
Study: 23663487

Group type: EXPERIMENTAL
Intervention: Pinna in forward position
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pinna in backward position
Number of subjects: 18
Study: 21878034

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) prior to Cognitive Behavioural Therapy (CBT)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cognitive Behavioural Therapy (CBT) alone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 35
Study: 19287017

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 735

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 735
Study: 18186171

Group type: EXPERIMENTAL
Intervention: 0.454% stabilized SnF2 sodium hexametaphosphate dentifrice
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sodium fluoride dentifrice (control)
Number of subjects: 75
Study: 15028439

Group type: EXPERIMENTAL
Intervention: Prophylactic protocol (40 mg mitomycin-C)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ablative protocol (80 mg mitomycin-C)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combined chemo-thermotherapy
Number of subjects: 52
Study: 11842896

Group type: EXPERIMENTAL
Intervention: G115 400 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: G115 200 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: G115 600 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: G115 200 mg and 400 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9712239

Group type: EXPERIMENTAL
Intervention: T cells expanded from the colon of patients with Crohn's disease (CD)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: T cells expanded from the colon of patients with ulcerative colitis (UC)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 43
Study: 7988622

Group type: EXPERIMENTAL
Intervention: Dilevalol 400 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2471287

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (about 840 mg, equivalent to 6 million Kallikrein inactivator units)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Untreated group (no aprotinin)
Number of subjects: 80
Study: 1103273

Group type: EXPERIMENTAL
Intervention: Carbenoxolone 100 mg three times daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Geranyl farnesyl acetate (Gefarnate) 100 mg three times daily
Number of subjects: 57
Study: 31192869

Group type: EXPERIMENTAL
Intervention: Postoperative anticoagulation (IV heparin or heparin with dextran)
Number of subjects: 282

Group type: COMPARATOR
Intervention: No postoperative anticoagulation
Number of subjects: 282
Study: 28167330

Group type: EXPERIMENTAL
Intervention: Triple P Online Brief (n=100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Waitlist Control (n=100)
Number of subjects: 200
Study: 26195265

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor sitagliptin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sulfonylurea (SU)
Number of subjects: 55
Study: 22929209

Group type: EXPERIMENTAL
Intervention: Commercial provider (Weight Watchers)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 772
Study: 21348806

Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg + glimepiride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg + glimepiride
Number of subjects: 0

Group type: COMPARATOR
Intervention: rosiglitazone 4 mg + glimepiride
Number of subjects: 0
Study: 18959634

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 601

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 601
Study: 16485321

Group type: EXPERIMENTAL
Intervention: Postictal scan in patients
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Interictal scan in patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group scans
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inter-group comparison
Number of subjects: 10
Study: 14614218

Group type: EXPERIMENTAL
Intervention: Isoflavone extract (61.8 mg) for three months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 22
Study: 10901342

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 8750523

Group type: EXPERIMENTAL
Intervention: Ovarian irradiation (R) 2000 rads in 5 days
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Ovarian irradiation plus prednisone (R + P) 7.5 mg daily for up to five years
Number of subjects: 703

Group type: COMPARATOR
Intervention: No further therapy (NT)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Ovarian irradiation (R)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Ovarian irradiation plus prednisone (R + P)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Ovarian irradiation with or without prednisone therapy
Number of subjects: 703
Study: 1421933

Group type: EXPERIMENTAL
Intervention: Oral gentamicin (10 mg/kg body weight/day for five days)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Oral gentamicin and placebo
Number of subjects: 92
Study: 4082295

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Alizapride (ALZ)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) in cisplatin-treated patients
Number of subjects: 82

Group type: COMPARATOR
Intervention: Alizapride (ALZ) in cisplatin-treated patients
Number of subjects: 82
Study: 29309883

Group type: EXPERIMENTAL
Intervention: Target depth of 4.0-5.0 cm
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Target depth of 4.5-5.5 cm
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Target depth of 5.0-6.0 cm
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall performance
Number of subjects: 100
Study: 27377549

Group type: EXPERIMENTAL
Intervention: Medication Review Tool
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 24353124

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 107

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 107
Study: 22371092

Group type: EXPERIMENTAL
Intervention: Drag suit training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (typical training attire)
Number of subjects: 18
Study: 21265353

Group type: EXPERIMENTAL
Intervention: Restricted fluid resuscitation (no induction bolus, then LR 2 mL/kg/h)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard fluid resuscitation (500 LR induction bolus, then LR 7 mL/kg/h x 1 h, then 5 mL/kg/h)
Number of subjects: 27
Study: 18504252

Group type: EXPERIMENTAL
Intervention: Standard radiosensitised induction chemoradiotherapy (arm A) with cisplatin (90 mg/m(2) day 1) plus etoposide
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Daily radiosensitised induction chemoradiotherapy (arm B) with cisplatin (6 mg/m(2)/day) plus etoposide
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard radiosensitised induction chemoradiotherapy (arm A)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Daily radiosensitised induction chemoradiotherapy (arm B)
Number of subjects: 204
Study: 15591305

Group type: EXPERIMENTAL
Intervention: n-3 substituted diet (N3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular high-fat diet (HF)
Number of subjects: 0
Study: 12942708

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanic acid
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 138
Study: 11074201

Group type: EXPERIMENTAL
Intervention: Single‐balloon expandable tubular stent
Number of subjects: 32
Study: 8796462

Group type: EXPERIMENTAL
Intervention: Family scenario
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Context-free list
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Cultural context
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Narrative data
Number of subjects: 187
Study: 1536352

Group type: EXPERIMENTAL
Intervention: AIDS risk reduction intervention
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control intervention on career opportunities
Number of subjects: 157
Study: 6365409

Group type: COMPARATOR
Intervention: Angiotensin II infusion alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion with prostaglandin E2
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 administration alone
Number of subjects: 25
Study: 31671873

Group type: EXPERIMENTAL
Intervention: Aromatherapy combined with music therapy
Number of subjects: 98
Study: 28602779

Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg per day fasted
Number of subjects: 231

Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Ceritinib
Number of subjects: 231

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 231
Study: 25989338

Group type: EXPERIMENTAL
Intervention: Briakinumab 200 mg
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Briakinumab 400 mg
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Briakinumab 700 mg
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 24099474

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rabeprazole 10 mg twice daily
Number of subjects: 40
Study: 21417971

Group type: EXPERIMENTAL
Intervention: Formaldehyde treatment of temporalis muscle fascia grafts
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (no formaldehyde treatment)
Number of subjects: 54
Study: 19113796

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine and sertraline, mirtazapine, and nefazodone as pharmacologic therapy for depression in heart failure patients.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers in patients with depression and heart failure.
Number of subjects: 0
Study: 17000930

Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study: 15849399

Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae positive (7/51 children with asthma)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis positive (2/51 patients with asthma)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Infected children with chlamydial IgA
Number of subjects: 51
Study: 11574184

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg alone for 30 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: CEE + continuous combined medroxyprogesterone acetate (MPA) 2.5 mg/daily for 28 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: CEE + cyclical MPA (10 mg o.d. from day 16 to day 28)
Number of subjects: 18
Study: 9625845

Group type: EXPERIMENTAL
Intervention: Paclitaxel (TX) 175 mg/m2 by 3 h i.v. infusion every 21 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Paclitaxel (TX)
Number of subjects: 70
Study: 8160217

Group type: EXPERIMENTAL
Intervention: Medical therapy and carotid endarterectomy
Number of subjects: 444

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 444
Study: 3116132

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) for 9.7 +/- 1.1 days
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study: 30201128

Group type: EXPERIMENTAL
Intervention: Wavefront-guided laser in situ keratomileusis (LASIK)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Wavefront-guided photorefractive keratectomy (PRK)
Number of subjects: 34
Study: 26599376

Group type: EXPERIMENTAL
Intervention: Aspirin intake at 8.00 AM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin intake at 8.00 PM
Number of subjects: 0
Study: 25611785

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment in the GLUCOLD trial
Number of subjects: 89

Group type: COMPARATOR
Intervention: Asthma-associated gene signatures in COPD
Number of subjects: 89
Study: 23820669

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise (GT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study: 22071933

Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no LIPUS)
Number of subjects: 36
Study: 19238075

Group type: EXPERIMENTAL
Intervention: Zoledronic acid and interleukin-2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zoledronic acid alone
Number of subjects: 0
Study: 16403243

Group type: EXPERIMENTAL
Intervention: Combined cognitive behavioral therapy (CBT) and pharmacotherapy intervention
Number of subjects: 232

Group type: COMPARATOR
Intervention: Usual primary-care treatment
Number of subjects: 232
Study: 12602908

Group type: EXPERIMENTAL
Intervention: DCT 50 mg/m2 bimonthly schedule
Number of subjects: 3

Group type: COMPARATOR
Intervention: DCT 75 mg/m2 every 3 weeks (calibration arm)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: DCT 60 mg/m2 bimonthly schedule
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: DCT 40 mg/m2 bimonthly schedule
Number of subjects: 3

Group type: COMPARATOR
Intervention: DCT 75 mg/m2 every 3 weeks
Number of subjects: 3
Study: 10885599

Group type: EXPERIMENTAL
Intervention: FEC/EM + LND
Number of subjects: 326

Group type: COMPARATOR
Intervention: FEC/EM
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: EM+/‐LND
Number of subjects: 326

Group type: COMPARATOR
Intervention: FEC+/‐LND
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: LND arms
Number of subjects: 326
Study: 9100679

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (three perioperative doses of cefazolin)
Number of subjects: 250

Group type: COMPARATOR
Intervention: No prophylaxis (NONE group)
Number of subjects: 250
Study: 8350342

Group type: EXPERIMENTAL
Intervention: Evaluation Condition (subjects told their performance was being evaluated and videotaped)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonevaluation Condition (subjects told their performance was not being observed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Task performance
Number of subjects: 0
Study: 3646271

Group type: EXPERIMENTAL
Intervention: Individually planned consecutive teaching sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 31679753

Group type: EXPERIMENTAL
Intervention: Psychological treatments for depression
Number of subjects: 465
Study: 29248995

Group type: EXPERIMENTAL
Intervention: 5L-SP approach
Number of subjects: 1399

Group type: COMPARATOR
Intervention: Crosswalk
Number of subjects: 1399

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 1399
Study: 27273710

Group type: EXPERIMENTAL
Intervention: SFC50 (salmeterol xinafoate 50 μg/day and fluticasone propionate 100 μg/day)
Number of subjects: 35
Study: 24548866

Group type: EXPERIMENTAL
Intervention: FOLFOX‐4 (5‐fluorouracil (5‐FU)+oxaliplatin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: XELOX (capecitabine+oxaliplatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FOLFOX‐4 (5‐fluorouracil (5‐FU)+oxaliplatin) with pump malfunction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FOLFOX‐4 (5‐fluorouracil (5‐FU)+oxaliplatin) without pump malfunction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pump malfunctions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efficacy outcomes
Number of subjects: 0
Study: 22987918

Group type: EXPERIMENTAL
Intervention: Low Na(+) diet (10 mmol/d)
Number of subjects: 185

Group type: COMPARATOR
Intervention: High Na(+) diet (300 mmol/d)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: SNPs in SLC4A5 (rs7571842 and rs10177833)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: SNPs in GRK4
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: SLC4A5 SNPs after adjustment for BMI and age
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Meta-analysis of SNPs rs7571842 and rs1017783
Number of subjects: 185
Study: 20566010

Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin oral tablets once daily (GB)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (GA)
Number of subjects: 150
Study: 18949104

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET) combined with irbesartan
Number of subjects: 21

Group type: COMPARATOR
Intervention: Aerobic exercise training (AET) with placebo
Number of subjects: 21
Study: 16481664

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) 10, 16, 20, and 27 mg applied in the morning for 9 hours
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 12540224

Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Periapical diagnosis of acute apical periodontitis
Number of subjects: 45
Study: 10849524

Group type: EXPERIMENTAL
Intervention: PBPC (Peripheral Blood Progenitor Cells)
Number of subjects: 61

Group type: COMPARATOR
Intervention: BM (Bone Marrow)
Number of subjects: 61
Study: 9095512

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies in 'Other Blood Groups'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard red cell serological techniques
Number of subjects: 0
Study: 8250363

Group type: EXPERIMENTAL
Intervention: 5 mg midazolam orally and 0.2 mg sublingual buprenorphine (group 2)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: 5 mg midazolam orally and 0.4 mg sublingual buprenorphine (group 3)
Number of subjects: 287

Group type: COMPARATOR
Intervention: 5 mg midazolam orally (group 1)
Number of subjects: 287
Study: 3879105

Group type: EXPERIMENTAL
Intervention: 24R,25 (OH)2D3 (10 micrograms daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31074641

Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment of physician's choice (control)
Number of subjects: 0
Study: 28724547

Group type: EXPERIMENTAL
Intervention: Aliskiren (6 months)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (6 months)
Number of subjects: 21
Study: 25538178

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg monotherapy (V)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg plus gemcitabine (V/G)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Gemcitabine plus placebo (G/P)
Number of subjects: 173
Study: 23161001

Group type: EXPERIMENTAL
Intervention: Yohimbine 16.2 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Yohimbine 32.4 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydromorphone 1 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hydromorphone 2 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Yohimbine (all doses)
Number of subjects: 10
Study: 21692277

Group type: EXPERIMENTAL
Intervention: Chonggu (EX‐HN 27) deep insertion group
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Chonggu (EX‐HN 27) shallow insertion group
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Traditional acupuncture group
Number of subjects: 283
Study: 19238452

Group type: EXPERIMENTAL
Intervention: Simvastatin (5 mg for children ≤30 kg, 10 mg for children >30 kg, doubled for two additional months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25